Advertisement
Australia markets close in 4 hours 18 minutes

  • ALL ORDS

    7,944.50
    +6.60 (+0.08%)
     

  • ASX 200

    7,690.00
    +6.50 (+0.08%)
     

  • AUD/USD

    0.6522
    +0.0034 (+0.52%)
     

  • OIL

    83.32
    -0.04 (-0.05%)
     

  • GOLD

    2,332.80
    -9.30 (-0.40%)
     

  • Bitcoin AUD

    102,493.34
    -117.24 (-0.11%)
     

  • CMC Crypto 200

    1,437.15
    +22.39 (+1.58%)
     

  • AUD/EUR

    0.6086
    +0.0030 (+0.49%)
     

  • AUD/NZD

    1.0979
    +0.0049 (+0.45%)
     

  • NZX 50

    11,862.83
    +59.55 (+0.50%)
     

  • NASDAQ

    17,471.47
    +260.59 (+1.51%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • Dow Jones

    38,503.69
    +263.71 (+0.69%)
     

  • DAX

    18,137.65
    +276.85 (+1.55%)
     

  • Hang Seng

    16,986.76
    +157.83 (+0.94%)
     

  • NIKKEI 225

    38,239.72
    +687.56 (+1.83%)
     

Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference

Oyster Point Pharma, Inc.
·1-min read

PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Thursday, December 3, 2020 and host investor meetings.

About Oyster Point Pharma
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. OC-01 nasal spray’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.

Investor Contact:
Tim McCarthy
LifeSci Advisors, LLC
(212) 915-2564
investors@oysterpointrx.com

Media Contact:
Sheryl Seapy, W2O Group
(213) 262-9390
sseapy@w2ogroup.com